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Abstract: Most incident coronary disease occurs in previously asymptomatic individuals who were considered to be at a 
lower risk by traditional screening methods. There is a definite advantage if these individuals could be reclassified into a 
higher risk category, thereby impacting disease outcomes favorably. Coronary artery calcium scores have been recognized 
as an independent marker for adverse prognosis in coronary disease. Multiple population based studies have acknowl-
edged the shortcomings of risk prediction models such as the Framingham risk score or the Procam score. The science be-
hind coronary calcium is discussed briefly followed by a review of current thinking on calcium scores. An attempt has 
been made to summarize the appropriate indications and use of calcium scores. 
INTRODUCTION 
  The 2008 report from the American Heart Association 
Statistics Committee and Stroke Statistics Subcommittee 
includes some sobering projections on the outlook for Coro-
nary Artery Disease in the current year. Approximately 
770,000 Americans are expected to have a new myocardial 
infarction and about 430,000 will have a recurrent heart at-
tack [1]. This amounts to an American experiencing a coro-
nary event every 26 seconds and a resultant fatality every 
minute [1]. Diseases of the heart continue to rank as the lead-
ing killer for both sexes in this country and account for 
27.2% of total deaths [2].  
RISK FACTORS FOR CORONARY ARTERY DIS-
EASE 
  In no other disease entity is the assessment of risk factors 
more important, than in CAD. This is due to cost implica-
tions and also due to the fact that events, sometimes fatal, 
can be averted. Risk stratification in CAD assumes greater 
importance also because it determines the type of tests that 
may be ordered by a clinician and also helps him or her 
choose between invasive and non-invasive treatment modali-
ties [3].  
  The Framingham risk score was based on data from the 
Framingham Heart Study, one of the longest running pro-
spective studies on CAD, and estimates 10-year coronary 
heart disease outcomes. It includes age, sex, total cholesterol, 
HDL cholesterol, smoking status, systolic blood pressure and 
use of anti-hypertensives [4]. It has long been acknowledged 
that these so called “traditional risk factors” are unable to 
account for all cases of CAD. It is also evident that the   
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findings from the Framingham cohort cannot be generalized 
to the rest of the population or other ethnic groups, as that 
was a study done on an almost entirely Caucasian popula-
tion. There is also a concern that the model routinely under-
estimates coronary risk in women and African Americans of 
either sex [5]. This has spurred interest in the quest for novel 
cardiovascular risk factors. Examples include, CRP, Lipo-
protein-A, Homocysteine, abdominal obesity, coronary ar-
tery calcium, carotid intima media thickness, lack of physical 
activity and psychosocial stress to name just a few.  
  This review tries to synthesize the current literature on 
coronary artery calcium and its detection by CT as a tool for 
risk assessment. We have also touched upon novel imaging 
techniques that incorporate functional and anatomic data in 
newer hybrid techniques that help in clinical decision mak-
ing. 
THE ROLE OF CALCIUM IN THE ATHEROSCLE-
ROTIC PLAQUE 
  It will be useful to recapitulate the evolution of the athe-
rosclerotic plaque and the role of calcium at a microscopic 
and macroscopic level in it. Endothelial cells, leukocytes and 
intimal smooth muscle cells are the main cellular agents re-
sponsible for atherosclerosis. Exposure of vascular endothe-
lium to atherogenic stimuli results in extra cellular lipid ac-
cumulation which leads to recruitment of leukocytes. The 
major leukocytes involved in this process are monocytes and 
T-Lymphocytes. The monocytes subsequently imbibe lipid 
and evolve into the “foam cell” or lipid laden macrophage 
which is considered the pathological hallmark of the athero-
sclerotic plaque. CAC occurs, and increases with age and 
develops in advanced atherosclerotic plaques although it is 
worth noting that absence of calcification does not imply 
absence of atherosclerosis [6]. The non-calcified atheroscle-
rotic lesions (NCALs) or “soft plaques” occupy a very 
prominent role in CAD as they are thought to be more unsta-
ble and therefore more “vulnerable”. However, CAC is not 
specific for luminal obstruction as there are other factors that 
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arterial lumen and coronary blood flow. Arterial lumen was 
studied in humans and nonhuman primates by Clarkson, et 
al. who concluded that lack of remodeling may be a major 
factor in certain individuals with coronary atherosclerosis 
not developing complications such as myocardial infarction 
[7].  
  Atherosclerotic calcification mainly involves the intimal 
layer of the artery as opposed to the more classical medial 
calcification (Monckeberg’s
  medial calcinosis), which is 
common in diabetic
 patients [8]. Numerous bone proteins are 
found in the atherosclerotic plaque and Osteopontin, a pro-
tein involved in mineralization has been specifically associ-
ated with calcific coronary atheroma and is thought to play 
an important role in the onset and progression of disease in 
humans [9]. Smooth muscle cells are thought to secrete cy-
tokines that facilitate calcium formation in the atheroma. In 
vitro studies have been performed, in which the ionic con-
centrations of calcium and phosphorous were simulated to 
mimic serum concentrations, and the resulting carbonate bio-
apatite precipitates were found to resemble closely, the calci-
fied atherosclerotic plaques seen in human blood vessels 
[10]. 
CALCIUM SCORES 
  The amount of calcium in the coronary arteries can be 
quantitated. Various methods have been proposed for this 
purpose. The most attractive and the most commonly used is 
the Agatston score. Other methods described include calcium 
volume and mass (mineral) scores. 
AGATSTON SCORES 
 Agatston,  et al. described a novel way of measuring 
coronary artery calcium in 1990 [11]. They used ultra fast 
CT to measure total calcium scores based on the number, 
areas and peak Hounsfield computed tomographic numbers 
of the calcific lesions detected. Subsequent studies have con-
firmed the high correlation between calcium scores and 
histopathologic coronary disease and also that absence of 
calcification was highly indicative of absence of CAD [12, 
13]. Inter reader variability of the Agatston score is about 
3%, intra reader variability is less than 1% and inter scan 
variability is thought to be about 15% [11].  
VOLUME SCORE 
  The calcium volume can be calculated by multiplying the 
number of voxels (Vn) with the voxel volume (Vv ) using a 
technique of isotropic interpolation as mentioned by Callis-
ter et al. [14]. The main limitations of this technique, are that 
a third spatial dimension of the plaque is not taken into ac-
count, and that, there is introduction of an arbitrary attenua-
tion scaling factor [14]. 
MASS SCORE 
  The mass score is calculated as the product of the cal-
cium concentration and calcified plaque volume [15].  
CALCIUM SCORE IN PREDICTING THE RISK OF 
CARDIAC EVENTS 
  Coronary calcium does predict risk since, in some meas-
ure it quantifies the total atherosclerotic burden [16]. A ma-
jority of acute cardiovascular events, i.e., strokes and myo-
cardial infarctions occur in subjects who are not considered 
to be at high risk for these events by traditional screening 
techniques in vogue, for e.g., the Framingham Risk Score or 
Procam score. Furthermore, calcification is known to be in-
timately associated with atherosclerosis even from a pre-
atheroma stage and is known to increase with age [17, 18]. 
Large observational cohorts studied to date, with zero cal-
cium scores are known to have a low adverse cardiac event 
risk [19]. A large observational cohort of over 25,000 as-
ymptomatic subjects was followed in a study by Budoff et 
al. in which coronary artery calcification (CAC) was found 
to be an independent predictor for all cause mortality [20].  
  There is a wealth of data which supports the use of CAC 
as a surrogate for coronary atherosclerosis confirmed by cor-
relation of angiographic, histopathologic and necropsy stud-
ies [21, 22]. It was shown by Mautner et al. that the amount 
of calcium deposits measured by EBCT correlates very well 
with histomorphometric measurements [23]. A study by 
Rumberger  et al. demonstrated that increasing amounts of 
coronary artery calcium by CT were found to correlate with 
more advanced atherosclerotic involvement of the coronaries 
detected by histological section [24]. 
CALCIUM SCORE IN COMPARISON TO TRADI-
TIONAL RISK FACTORS 
  The importance of a risk assessment tool to transcend 
racial and ethnic barriers cannot be over emphasized given 
the rapidly shifting demographic patterns in the United 
States and the rest of the world. The FRS was developed 
originally in an almost exclusively Caucasian population 
which results in erroneous risk estimations when applied to a 
broader population which includes other ethnic groups. Cli-
nicians may be disinclined to incorporate risk prediction 
models and treatment guidelines derived from them if the 
risk prediction functions do not have good portability outside 
the settings where they were originally conceived [25]. In-
vestigators have circumvented this problem by either recali-
brating these tools or combining with them additional tests 
such as CAC [26]. 
  More recently, data from the Multi-Ethnic Study of Athe-
rosclerosis (MESA) cohort which had multi racial represen-
tation was used to demonstrate that CAC is a strong predic-
tor of incident coronary disease and provided predictive in-
formation beyond that was provided by traditional risk fac-
tors [27]. This was demonstrated in all the major racial 
groups studied and is therefore a major advantage of CAC 
over the FRS.  
CLINICAL APPLICATIONS OF CALCIUM SCORING  
  The value of any clinical test depends on its ability to 
primarily, diagnose a condition and secondarily, to help im-
part changes that alter the natural history of the disease and 
thereby improve outcomes. Coronary artery calcium has the 
unique status of being a risk factor for CAD and at the same 
time can be imaged by CT.  
 Schenker,  et al. have shown that evaluation of atheroscle-
rotic disease burden anatomically by CAC scores, provides 
incremental prognostic information when coupled with 
physiologic data from myocardial perfusion imaging [28]. 
Another application is use of Cardiac CT as a gatekeeper to 
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evaluated in a setting such as the emergency room. In this 
context, absence of CAC would be predictive of a normal 
PET study and could thus be potentially avoided. This has 
been demonstrated by Esteves, et al. who found that such an 
approach would be cost effective, minimize radiation expo-
sure and likely decrease length of stay in the hospital [29]. 
The pairing of complementary imaging technologies such as 
CT and PET, which provide anatomic and physiologic data 
respectively, has spawned Hybrid PET-CT techniques for the 
detection of CAD. Sampson et al. have reported the use of 
rubidium-82 myocardial perfusion PET-CT with sensitivity 
up to 93% and specificity of 83% for the detection of ob-
structive CAD [30].  
  In the Multi-Ethnic Study of Atherosclerosis (MESA) 
study, Wang et al. studied a patient population that did not 
carry a diagnosis of CAD. The parameters that were meas-
ured in this study included myocardial blood flow measured 
using MRI, during rest and adenosine induced hyperemia 
and Agatston scores for coronary calcification measured by 
multi-detector CT. The study showed that independent of the 
presence of risk factors for CAD, myocardial perfusion re-
serve was inversely correlated with the presence and severity 
of CAC in asymptomatic adults [31]. In the PACC (Prospec-
tive Army Coronary Calcium) project Taylor, et al. in a 
study of 2000 subjects found that coronary calcium provides 
substantial, independent prognostic information in predicting 
new onset CAD [32]. The status of the calcium score as an 
independent predictor for coronary events has been estab-
lished based on meta analyses of various studies by Pletcher, 
et al. (Table 1) [33].  
Table  1.  Adjusted Odds Ratios (OR) Comparing Risk of A 
Coronary Heart Disease Event in Persons with Low 
(1-100), Medium (101-400), and High (>400) Coro-
nary Artery Calcium (CAC) Scores to Persons With- 
out Calcification. 95% Confidence Intervals are 
Given in Parenthesis (P<.001)
a 
 
CAC Score  Adjusted Odds Ratio 
1-100 2.1(1.6-2.9) 
101-400 5.4(2.2-13) 
>400 10(3.1-34) 
aRef. [33].  
  Results from the Rotterdam Coronary Calcification study 
which involved over 2000 elderly subjects demonstrated 
that, risk prediction based on cardiovascular risk factors im-
proved when coronary calcification was added to the model 
[34]. CAC measured by CT can identify a high risk group 
with silent myocardial ischemia who can than be selected for 
further intensive therapeutic options and, or, invasive angi-
ography after SPECT [35]. Moser et al. have established an 
Agatston score of 400 as a threshold number for initiating 
myocardial SPECT testing; also an Agatston score less than 
100 is very unlikely to be associated with an abnormal 
SPECT study [36]. In the same context it has been noted that 
an Agatston score greater than 400 in patients who are re-
ceiving appropriate medical therapy for CAD is associated 
with ischemia implying that these patients may need to be  
 
managed differently [37]. In another more recent study by 
Ho, et al. it was found that, as CAC scores increased, there 
was an increase in the frequency of MDCT detected obstruc-
tive stenosis, a relation which was maintained after adjust-
ment for traditional risk factors [38]. A similar conclusion 
was arrived at by a prospective study of over 10,000 subjects 
conducted by Church, et al. who conclude that CAC can 
identify individuals at increased risk of CAD death or non-
fatal MI who would otherwise be considered low risk [39].  
  In a study of over 1700 asymptomatic subjects Becker, et 
al. demonstrated that by the determination of CAC, patients 
at a higher risk for CAD could be identified. In this study the 
Agatston score was compared with the ATP III risk score 
and the Procam score and was shown to have a higher diag-
nostic accuracy for CAD [40]. A smaller study by Achen-
bach,  et al. compared CAC measured by EBCT with pre-
dicted 10-year cardiovascular risk determined by FRS, ATP 
III and Procam and found that there was very low correlation 
between the two [41]. These studies which pitch CAC 
against traditional risk stratification models, highlight the 
disconnect between the various models and have brought 
CAC and other modalities to the forefront in the quest for 
newer, more reliable risk evaluation strategies. 
  The progression of CAC on serial EBCT was found to be 
greater in patients with future myocardial infarctions raising 
the possibility that patient subsets can be sampled out for 
follow up on serial exams especially for delineating response 
to therapy and improving risk profiles [42]. Even when used 
with dual source 64 CT, the combined use of CAC scores 
and CTA was found to improve the specificity of assessing 
coronary stenoses from 87% to 100% without decreasing 
sensitivity [43]. CAC can be used to distinguish ischemic 
from non-ischemic cardiomyopathy with the presence of 
calcium signifying ischemia as a potential etiology [44, 45]. 
Given the shortcomings of traditional risk factors in predicat-
ing cardiovascular events and the strength of CAC as an in-
dependent predictor for coronary events, new methods of 
risk prediction which incorporate both CAC and traditional 
risk factors have been introduced [46].  
LIMITATIONS 
  The calcium score may not give accurate risk estimates in 
special patient populations such as uremic subjects and 
should not be used as a test in isolation in the risk stratifica-
tion of these patients [47]. Another obvious disadvantage is 
the use of CT and concomitant radiation exposure. The mag-
nitude of radiation exposure depends among other factors on 
EKG pulsing and certain studies have quoted radiation doses 
up to 21.4 mSv without the use of EKG pulsing compared to 
a mean of 5.6 mSv for diagnostic catheter angiographies 
[48]. Hausleiter, et al. report that the average radiation dose 
estimates ranged from a mean of 6.4±1.9 and 11.0±4.1 mSv 
for 16- and 64-slice
 CT, respectively. They further note, that 
decrease in radiation exposure can be achieved by EKG-
dependent dose modulation
 , reduced tube voltage and most 
importantly better patient selection [49]. Ongoing advances 
in CT technology could in the near future decrease the 
amount of radiation dose considerably. It must be mentioned 
that cost is another factor which makes CAC less appealing 
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CONCLUSION 
  Calcium scores appear to be a new and formidable com-
ponent of the armamentarium at the clinicians’ disposal, one 
we think has already started to impact the practice of cardio-
vascular medicine favorably. Taylor, et al. mention an inde-
pendent three fold greater likelihood of use of statins and 
aspirin in a follow up study on their PACC project cohort 
which used CAC [50]. Combining calcium scores with other 
techniques such as MPS, results in better patient selection for 
invasive and potentially more expensive treatment options, 
which translates into better outcomes and more health care 
dollars saved. 
  The quest for new clinical tools to better risk stratify pa-
tients, particularly the elderly is gaining momentum. Fur-
thermore, in the elderly, especially over the age of 50 years, 
the association of risk factors like cholesterol, with mortality 
is confounded by the presence of comorbidities [51]. How-
ever more clinical studies may have to be done before cal-
cium scores and Cardiac CT are able to find a better defined 
role in the diagnostic algorithms for coronary disease. The 
ACCF/AHA consensus statement on the subject considers 
the use of CAC scores favorably, especially in intermediate 
risk patient populations based on the possibility that they 
may be reclassified into a higher risk status based on calcium 
scores, a decision that could impact their subsequent treat-
ment plans and also clinical outcome [52]. The adoption of 
nascent technology is turbulent in all disciplines and cardio-
vascular medicine is no exception. There is a raging contro-
versy over the suggested use of CT or Ultrasound in asymp-
tomatic individuals (the SHAPE taskforce recommendations) 
with the aim to institute pharmacological prevention, an is-
sue that raises scientific and financial controversy. The rami-
fications arising from the above, especially the economic 
implications, are dissected by Diamond, et al. (Table 2) in 
great detail [53, 54].  
  A full discussion of the SHAPE task force recommenda-
tions, and the controversies arising there from, is beyond the 
scope of this review. Dr. Harvey Hecht laments on the sub-
ject in his well written take on the matter, that (it) is “incum-
bent on the cardiology community to temper the inflexible 
need for randomized trials with the reality of 565,000 pa-
tients presenting with myocardial infarctions annually as 
their first symptoms, 95% of whom could be identified as at 
high risk by CAC screening and aggressively treated to sig-
nificantly reduce events” [55]. It may be prudent at this point 
to summarize the appropriateness criteria for CAC as advo-
cated by the ACCF/AHA consensus document (Table 3) 
[52].  
Table 3.  Appropriateness Criteria for Calcium Score Estimation as Recommended by ACCF/AHA
c 
Clinical Scenario  Recommendations  Comment 
Asymptomatic patients with interme-
diate CHD risk(10-20% 10 year risk) 
May be reasonable to use CAC.  These patients may be reclassified to a higher risk status 
based on CAC and management may be modified. 
Patients with low CHD risk( <10% 10 
year risk) 
Does not recommend use of CAC.  Such use is similar to population screening scenario. 
Asymptomatic patients with >20% 10 
year CHD risk 
Does not recommend use of CAC.  These patients are already candidates for intensive risk 
reduction. 
Patients with CAC=0 who are other-
wise intermediate risk 
No evidence available for consensus judgment.  Recommendations for intermediate risk patients should 
apply. 
Patients with intermediate risk and 
choice of alternate tests 
CAC has not been compared head to head with 
other tests. 
Cannot be answered based on current evidence. 
High CAC  Additional non-invasive testing is not recom-
mended. 
High risk patients with multiple risk factors or Diabetes 
should get intensive therapy. 
Patients with atypical symptoms  Low risk patients with atypical symptoms may 
benefit from CAC testing. 
Other competing tests are also available with no head to 
head comparisons done. 
Specific population groups  Available data are strongest for Caucasian, non-
Hispanic men. 
Caution should be exercised in extrapolation of data to 
women, African American men. 
Incidental findings on CAC  Appropriate follow up per radiology guidelines.  For example guidelines for small pulmonary nodules. 
cRef. [54] 
Table 2.  Cost Effectiveness of Alternative Strategies for Cardiovascular Prevention (in $1000)
b 
 
Measure  Shape vs. NCEP  Treat All vs. NCEP  Treat All vs. Shape 
Gross cost per life saved  $1467  $1346  $1167 
Gross cost per life-year saved  $113  $104  $90 
Gross cost per LYE saved  $49  $45  $39 
Net cost per LYE saved  $32  $28  $22 
{LYE=Life year; SHAPE= Screening for Heart Attack Prevention and Education; 
NCEP= National Cholesterol Education Program} 
bRef. [52] Coronary Artery Calcium Scores  The Open Cardiovascular Medicine Journal, 2008, Volume 2    91 
  Although calcium score estimation is quite promising as 
a risk estimator, it is worth noting, that the premise does not 
exist at least currently, to endorse population based screen-
ing for coronary calcium. The place of CAC in the risk man-
agement algorithms for cardiovascular diseases is unsettled 
at this time, but promises to be a vexing question, given the 
shortcomings engendered by traditional risk scores. 
ABBREVIATIONS 
CAD  =  Coronary Artery Disease 
CT =  Computed  Tomography 
CAC =  Coronary  Artery  Calcium 
FRS = Framingham  Risk  Score 
EBCT  =  Electron Beam Computed Tomography 
PET = Positron  Emission  Tomography 
MRI = Magnetic  Resonance  Imaging 
MPS = Myocardial  Perfusion  Scintigraphy 
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